Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor
Rilpivirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved for HIV-1 treatment-naive adult patients in combination with other antiretroviral agents. The recommended dose is a 25 mg tablet once daily taken orally with a meal. Due to cytochrome P450 3A4 enzyme inducti...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2013-02, Vol.68 (2), p.250-256 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 256 |
|---|---|
| container_issue | 2 |
| container_start_page | 250 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 68 |
| creator | Sharma, Mamta Saravolatz, Louis D |
| description | Rilpivirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved for HIV-1 treatment-naive adult patients in combination with other antiretroviral agents. The recommended dose is a 25 mg tablet once daily taken orally with a meal. Due to cytochrome P450 3A4 enzyme induction or gastric pH increase, rilpivirine cannot be coadministered with a number of other drugs (anticonvulsants, rifabutin, rifampicin, rifapentine, proton pump inhibitors, systemic dexamethasone and St John's wort). Rilpivirine should be used with caution when coadministered with a drug with a known risk for torsade de pointes. Rilpivirine has a better tolerability than a comparative NNRTI, efavirenz, in clinical trials, with fewer central nervous system adverse effects, rashes, lipid abnormalities and discontinuation rates. Virological failure occurs more commonly with higher baseline viral loads (>100,000 copies/mL) and lower baseline CD4 counts ( |
| doi_str_mv | 10.1093/jac/dks404 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1318696572</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1273506283</sourcerecordid><originalsourceid>FETCH-LOGICAL-p202t-5f75e8de155ae7b7d144e87dfb31df3e46eaa96b54cc678f028b655cd5644e663</originalsourceid><addsrcrecordid>eNqF0EtLw0AUBeBBFFurG3-ABNy4ib2TebsrxRcUBNF1mWRucGo6iTNJxX9vwLpx4-py4OPAuYScU7imYNh8Y6u5e08c-AGZUi4hL8DQQzIFBiJXXLAJOUlpAwBSSH1MJgUDY7SAKVk8-6bzOx99wJvMZgE_s9CGPAxVg23yDrOIO4wJsz7akKrou96OyYc3X_q-jafkqLZNwrP9nZHXu9uX5UO-erp_XC5WeVdA0eeiVgK1QyqERVUqRzlHrVxdMupqhlyitUaWgleVVLqGQpdSiMoJOUIp2Yxc_fR2sf0YMPXrrU8VNo0N2A5pTRnV0kihiv9poZgAWWg20ss_dNMOMYxDRiWNMgI4jOpir4Zyi27dRb-18Wv9-0f2Dfx7c5I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1269795040</pqid></control><display><type>article</type><title>Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Sharma, Mamta ; Saravolatz, Louis D</creator><creatorcontrib>Sharma, Mamta ; Saravolatz, Louis D</creatorcontrib><description>Rilpivirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved for HIV-1 treatment-naive adult patients in combination with other antiretroviral agents. The recommended dose is a 25 mg tablet once daily taken orally with a meal. Due to cytochrome P450 3A4 enzyme induction or gastric pH increase, rilpivirine cannot be coadministered with a number of other drugs (anticonvulsants, rifabutin, rifampicin, rifapentine, proton pump inhibitors, systemic dexamethasone and St John's wort). Rilpivirine should be used with caution when coadministered with a drug with a known risk for torsade de pointes. Rilpivirine has a better tolerability than a comparative NNRTI, efavirenz, in clinical trials, with fewer central nervous system adverse effects, rashes, lipid abnormalities and discontinuation rates. Virological failure occurs more commonly with higher baseline viral loads (>100,000 copies/mL) and lower baseline CD4 counts (<50 cells/mm(3)). Seventeen NNRTI mutations have been associated with decreased susceptibility to rilpivirine: K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, H221Y, F227C, M230I/L, Y188L and the combination L100I + K103N. Resistance to rilpivirine largely excludes future use of the NNRTI class.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dks404</identifier><identifier>PMID: 23099850</identifier><language>eng</language><publisher>England: Oxford Publishing Limited (England)</publisher><subject>Anticonvulsants ; Antiretroviral drugs ; Clinical trials ; Drug Interactions ; Drug Resistance, Viral ; Drug Therapy, Combination - methods ; Drug use ; HIV ; HIV Infections - drug therapy ; HIV Infections - virology ; HIV-1 - drug effects ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Humans ; Nitriles - adverse effects ; Nitriles - pharmacology ; Nitriles - therapeutic use ; Pyrimidines - adverse effects ; Pyrimidines - pharmacology ; Pyrimidines - therapeutic use ; Reverse Transcriptase Inhibitors - adverse effects ; Reverse Transcriptase Inhibitors - pharmacology ; Reverse Transcriptase Inhibitors - therapeutic use ; Rilpivirine ; Treatment Outcome ; Virology</subject><ispartof>Journal of antimicrobial chemotherapy, 2013-02, Vol.68 (2), p.250-256</ispartof><rights>Copyright Oxford Publishing Limited(England) Feb 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23099850$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sharma, Mamta</creatorcontrib><creatorcontrib>Saravolatz, Louis D</creatorcontrib><title>Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Rilpivirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved for HIV-1 treatment-naive adult patients in combination with other antiretroviral agents. The recommended dose is a 25 mg tablet once daily taken orally with a meal. Due to cytochrome P450 3A4 enzyme induction or gastric pH increase, rilpivirine cannot be coadministered with a number of other drugs (anticonvulsants, rifabutin, rifampicin, rifapentine, proton pump inhibitors, systemic dexamethasone and St John's wort). Rilpivirine should be used with caution when coadministered with a drug with a known risk for torsade de pointes. Rilpivirine has a better tolerability than a comparative NNRTI, efavirenz, in clinical trials, with fewer central nervous system adverse effects, rashes, lipid abnormalities and discontinuation rates. Virological failure occurs more commonly with higher baseline viral loads (>100,000 copies/mL) and lower baseline CD4 counts (<50 cells/mm(3)). Seventeen NNRTI mutations have been associated with decreased susceptibility to rilpivirine: K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, H221Y, F227C, M230I/L, Y188L and the combination L100I + K103N. Resistance to rilpivirine largely excludes future use of the NNRTI class.</description><subject>Anticonvulsants</subject><subject>Antiretroviral drugs</subject><subject>Clinical trials</subject><subject>Drug Interactions</subject><subject>Drug Resistance, Viral</subject><subject>Drug Therapy, Combination - methods</subject><subject>Drug use</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - virology</subject><subject>HIV-1 - drug effects</subject><subject>Human immunodeficiency virus</subject><subject>Human immunodeficiency virus 1</subject><subject>Humans</subject><subject>Nitriles - adverse effects</subject><subject>Nitriles - pharmacology</subject><subject>Nitriles - therapeutic use</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - pharmacology</subject><subject>Pyrimidines - therapeutic use</subject><subject>Reverse Transcriptase Inhibitors - adverse effects</subject><subject>Reverse Transcriptase Inhibitors - pharmacology</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>Rilpivirine</subject><subject>Treatment Outcome</subject><subject>Virology</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0EtLw0AUBeBBFFurG3-ABNy4ib2TebsrxRcUBNF1mWRucGo6iTNJxX9vwLpx4-py4OPAuYScU7imYNh8Y6u5e08c-AGZUi4hL8DQQzIFBiJXXLAJOUlpAwBSSH1MJgUDY7SAKVk8-6bzOx99wJvMZgE_s9CGPAxVg23yDrOIO4wJsz7akKrou96OyYc3X_q-jafkqLZNwrP9nZHXu9uX5UO-erp_XC5WeVdA0eeiVgK1QyqERVUqRzlHrVxdMupqhlyitUaWgleVVLqGQpdSiMoJOUIp2Yxc_fR2sf0YMPXrrU8VNo0N2A5pTRnV0kihiv9poZgAWWg20ss_dNMOMYxDRiWNMgI4jOpir4Zyi27dRb-18Wv9-0f2Dfx7c5I</recordid><startdate>201302</startdate><enddate>201302</enddate><creator>Sharma, Mamta</creator><creator>Saravolatz, Louis D</creator><general>Oxford Publishing Limited (England)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope><scope>7TM</scope></search><sort><creationdate>201302</creationdate><title>Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor</title><author>Sharma, Mamta ; Saravolatz, Louis D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p202t-5f75e8de155ae7b7d144e87dfb31df3e46eaa96b54cc678f028b655cd5644e663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Anticonvulsants</topic><topic>Antiretroviral drugs</topic><topic>Clinical trials</topic><topic>Drug Interactions</topic><topic>Drug Resistance, Viral</topic><topic>Drug Therapy, Combination - methods</topic><topic>Drug use</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - virology</topic><topic>HIV-1 - drug effects</topic><topic>Human immunodeficiency virus</topic><topic>Human immunodeficiency virus 1</topic><topic>Humans</topic><topic>Nitriles - adverse effects</topic><topic>Nitriles - pharmacology</topic><topic>Nitriles - therapeutic use</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - pharmacology</topic><topic>Pyrimidines - therapeutic use</topic><topic>Reverse Transcriptase Inhibitors - adverse effects</topic><topic>Reverse Transcriptase Inhibitors - pharmacology</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>Rilpivirine</topic><topic>Treatment Outcome</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sharma, Mamta</creatorcontrib><creatorcontrib>Saravolatz, Louis D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Nucleic Acids Abstracts</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sharma, Mamta</au><au>Saravolatz, Louis D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2013-02</date><risdate>2013</risdate><volume>68</volume><issue>2</issue><spage>250</spage><epage>256</epage><pages>250-256</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><abstract>Rilpivirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved for HIV-1 treatment-naive adult patients in combination with other antiretroviral agents. The recommended dose is a 25 mg tablet once daily taken orally with a meal. Due to cytochrome P450 3A4 enzyme induction or gastric pH increase, rilpivirine cannot be coadministered with a number of other drugs (anticonvulsants, rifabutin, rifampicin, rifapentine, proton pump inhibitors, systemic dexamethasone and St John's wort). Rilpivirine should be used with caution when coadministered with a drug with a known risk for torsade de pointes. Rilpivirine has a better tolerability than a comparative NNRTI, efavirenz, in clinical trials, with fewer central nervous system adverse effects, rashes, lipid abnormalities and discontinuation rates. Virological failure occurs more commonly with higher baseline viral loads (>100,000 copies/mL) and lower baseline CD4 counts (<50 cells/mm(3)). Seventeen NNRTI mutations have been associated with decreased susceptibility to rilpivirine: K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, H221Y, F227C, M230I/L, Y188L and the combination L100I + K103N. Resistance to rilpivirine largely excludes future use of the NNRTI class.</abstract><cop>England</cop><pub>Oxford Publishing Limited (England)</pub><pmid>23099850</pmid><doi>10.1093/jac/dks404</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2013-02, Vol.68 (2), p.250-256 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1318696572 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | Anticonvulsants Antiretroviral drugs Clinical trials Drug Interactions Drug Resistance, Viral Drug Therapy, Combination - methods Drug use HIV HIV Infections - drug therapy HIV Infections - virology HIV-1 - drug effects Human immunodeficiency virus Human immunodeficiency virus 1 Humans Nitriles - adverse effects Nitriles - pharmacology Nitriles - therapeutic use Pyrimidines - adverse effects Pyrimidines - pharmacology Pyrimidines - therapeutic use Reverse Transcriptase Inhibitors - adverse effects Reverse Transcriptase Inhibitors - pharmacology Reverse Transcriptase Inhibitors - therapeutic use Rilpivirine Treatment Outcome Virology |
| title | Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T02%3A21%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rilpivirine:%20a%20new%20non-nucleoside%20reverse%20transcriptase%20inhibitor&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Sharma,%20Mamta&rft.date=2013-02&rft.volume=68&rft.issue=2&rft.spage=250&rft.epage=256&rft.pages=250-256&rft.issn=0305-7453&rft.eissn=1460-2091&rft_id=info:doi/10.1093/jac/dks404&rft_dat=%3Cproquest_pubme%3E1273506283%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1269795040&rft_id=info:pmid/23099850&rfr_iscdi=true |